Irish biotech firm wins €3m in bid to push diabetes breakthrough over line
Patented peptide which normalises blood sugars now mobilised in race against global epidemic
Biotech and R&D company Nuritas has secured funding to push ahead with an ingredient that potentially halts the inexorable slide into diabetes of pre-diabetic patients.
The scientifically validated and patent-filed peptide represents a major breakthrough in the battle to prevent type two diabetes.
The revolutionary ingredient is sourced from nature and will stand alone as the world's first treatment to halt progression into diabetes.
'The vast majority of patients with pre-diabetes will slide ...
